Human bactericidal antibody response to meningococcal outer membrane protein vaccines.
Antonie Van Leeuwenhoek
; 53(6): 403-11, 1987.
Article
en En
| MEDLINE
| ID: mdl-3130779
Several different meningococcal outer membrane protein vaccines have been prepared and used in human safety and immunogenicity studies. The results of these studies have led to some general conclusions regarding the human antibody response to these vaccines. A review of these conclusions, however, indicates that a number of important questions and problems still need to be addressed. Two of these are the determination of the protective level of bactericidal antibody in human serum and the impact of phase variation of surface antigens on vaccine strategy. Bactericidal assays using intrinsic complement and high concentrations of serum suggest that the level of natural immunity to group B meningococci is quite high, but is increased by vaccination with outer membrane protein vaccine. Phase variation in meningococcal surface antigens including capsule, class 1 protein, class 5 protein, and lipopolysaccharide was demonstrated using colony blotting with monoclonal antibodies. Phase variation resulted in differences in susceptibility to the bactericidal activity of human sera.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Proteínas de la Membrana Bacteriana Externa
/
Vacunas Bacterianas
/
Anticuerpos Antibacterianos
/
Antígenos Bacterianos
/
Neisseria meningitidis
Límite:
Humans
Idioma:
En
Revista:
Antonie Van Leeuwenhoek
Año:
1987
Tipo del documento:
Article
Pais de publicación:
Países Bajos